We have recently shown that an evolutionary conserved gene LAZ3, encoding a zinc finger protein, is disrupted and overexpressed in some B-cell lymphomas (mainly with a large cell component) that show chromosomal rearrangements involving 3q27. Because the breakpoints involved in these rearrangements are focused in a narrow major translocation cluster (MTC) on chromosome 3, we used genomic probes from this region t o study the molecular rearrangements of LAZ3 in a large series of patients (217) with non-Hodgkin's lymphoma (NHL). Southern blot analysis showed LAZ3 rearrangement in 43 patients (19.8%). Rearrangement was found in 11 of the 84 patients (13%) with follicular lymphoma but was most frequent in aggressive lymphoma (diffuse mixed, diffuse large cell, and large cell immunoblastic subtypes), in which 31 of the 114 patients (27%) were affected. The highest proportion of LAZ3 alteration was observed in B-cell aggressive lymphoma (26 of 71 PECIFIC RECURRING chromosomal aberrations have been reported in most hematologic malignancies. In Bcell neoplasms, several translocations involve the Ig genes at bands 14q32,2p12, and 22qll.I The most frequent defects in non-Hodgkin's lymphoma (NHL) are the (14; 18) translocation, associated mainly with follicular lymphoma*; the (8; 14) translocation and its variants found in Burkitt's l y m p h~m a~.~; and the (1 1 ; 14) translocation associated with intermediate or "mantle zone" lymphoma. ' The molecular analysis of these chromosomal defects has shown that they lead to the oncogenic conversion of genes such as BCL-2,"' a regulator of apoptotic cell death: or of proto-oncogenes encoding transcription regulators such as MYC'03LL and CCND1/PRAD. '2"4 We have previously reported that translocations involving chromosome 3q27 and Ig gene regions are the third most common specific group of translocations in NHL, and are associated mainly with diffuse large cell lymphoma (DLCL)." In this subset of NHL, numerous chromosomal defects are found that affect the same region on chromosome 3 but not the Ig gene locations. We and others have shown that most of these rearrangements involve the same major translocation cluster (MTC) on chromosome 3.'h"8 These translocations result in the disruption and deregulation of a gene, LAZ3,I9 also named BCL-6," encoding a conserved zinc finger protein that may act as a transcriptional regulator involved in differentiation and development. To confirm the prominent role of the LAZ3 gene in the pathogenesis of NHL, we used genomic probes derived from the 3q27 MTC to study DNAs from a series of 217 patients with this disease.
MATERIALS AND METHODS

S
Patients. High molecular weight DNA was obtained from biopsy specimens of 217 adult patients admitted to the Centre Henri Becquerel (Rouen, France) between September 1984 and April 1993 for the diagnosis and treatment of NHL. Tissue samples. Fresh lymph nodes were divided for morphologic, immunologic, and cytogenetic studies as previously described." Cells were cryopreserved for various periods of time before DNA extraction. All histologic material was reviewed by the same pathologist and classified according to the Working Formulation for Clinical Usage." DNA extraction and Southern blot analysis. DNA was extracted by the sarkosyl-proteinase K-phenokhloroform method. After digestion with restriction endonucleases, DNA fragments were electrophoresed on 0.8% agarose gels, transferred onto nylon N+ membranes, and hybridized according to the recommendations of the suppliers (Amersham). DNAs were digested using at least two of four restriction enzymes (EcoRI, BamHI, HindIII, Xba I). The genomic probes F370, F372, and F381 (Fig 1) have been previously described.18
Cytogenetic analysis. Cells (2 X 10b/mL) were cultured overnight in RPM1 1640 supplemented with 10% fetal calf serum in the presence of colchicine (0.02 pg/mL). Cells were incubated for 25 Correlation with clinical presentation and outcome. For this retrospective study, we only considered patients who had a tumor sample studied at the time of primary diagnosis. Two patient populations were selected: patients with follicular lymphomas and patients with aggressive lymphomas as defined by the International Non-Hodgkin's Lymphoma Prognostic Factor Proje~t,'~ namely diffuse mixed, diffuse large cell, and large cell immunoblastic subtypes. For each population, the association between LAW rearrangement and clinical features was studied. The clinical features studied were: age, sex, performance status, presence of B symptoms, Ann Arbor stage, bone marrow involvement, number of extranodal sites, presence of a mass greater than 10 cm, LDH level, serum albumin level, and overall survival. For aggressive lymphoma only, association with the International Prognostic Index," response to treatment, and disease-free survival were also examined.
Statistical methods. Associations between LA23 rearrangement and initial clinical features were analyzed with the two-sided chisquared test. Survival curves were plotted using the method of Kaplan and Meief' and were compared by the log-rank test.26 Analyses were performed with use of JPSI statistical software (developed by P. Kwiatkowski, Centre Jean Perrin, Clermont-Ferrand, France).
RESULTS
LAZ3
rearrangements were detected in 43 of the 217 samples (19.8%). A common HindIII polymorphism was also noted in 15 patients. All histologic subtypes of the Working Formulation were represented in the patient population (Table l ) and the involvement of LA23 was observed in all of them, with the exception of lymphocytic, lymphoblastic, and diffuse small noncleaved cell lymphomas.
Eleven of the 84 follicular lymphomas (13%) were found to be rearranged. M 3 alterations appeared to be more frequent in large cell follicular lymphoma (4/10) than in small or mixed cell follicular lymphoma (7174). However, most of LAZ3 rearrangements were observed in aggressive lymphoma (diffuse mixed, diffuse large cell, and large cell immunoblastic), affecting 31 of the 114 patients in these subtypes (27%).
Immunophenotype could be determined in 204 tumors, which comprised 163 B-cell and 41 T-cell lymphomas. Of the 163 B-cell lymphomas (including follicular lymphomas), 38 were rearranged (Table 2) .
Within the subgroup of 71 patients with aggressive B-cell lymphoma, the LAZ3 gene was involved in 26 patients (37%), mainly with diffuse large cell (14/46) and immunoblastic (6/12) lymphomas. Only one patient with T-cell lymphoma was found to have an LAZ3 rearrangement. In this case, the results of morphologic evaluation and immunostaining were confirmed by the absence of Ig gene rearrangement and the presence of a C@ rearrangement. The only anaplastic large cell lymphoma of B-cell phenotype included in this study had an M 3 rearrangement, whereas four T-anaplastic large cell lymphomas appeared to be unaffected.
Good quality metaphases were obtained in 201 patients, 32 of which had a detectable abnormality of the 3q27 region (16%) ( Table 3) . LAZ3 rearrangement was found in 14 of the 18 patients with translocations involving 3q27 and Ig genes regions. Among the 14 patients with chromosomal 3q27 defects (12 translocations, 2 deletions) that did not affect Ig gene regions, 7 showed L A B rearrangements, as did 18 patients with no evident cytogenetic involvement of the 3q27 region. Thirteen of these had a complex karyotype, whereas 5 displayed a more simple pattern: 47,xyy; 46,xx, t(2; 18)(p12;q21); 46,xx, t(14; 18)(q32;q21); 47,xy, +5; 46,xx, t( 15;2O)(q22;ql3)/46,xx,der(9)(~24).
LAZ3 rearrangement was found to be associated, at the cytogenetic level, with other specific abnormalities in 12 of 39 patients. These translocations were at( 14; 18) or a t(2; 18) (Table 4 ) examined at the time of diagnosis, but no statistical correlations were observed in either subgroup. LAZj rearrangement did not influence survival in patients with follicular lymphoma (Fig 2) . The overall survival of patients with aggressive lymphoma and an L A U rearrangement appeared slightly better than those of patients without rearrangement, but the difference was not significant (P > .55) (Fig 3) .
DISCUSSION
Molecular studies of the t(14; 18) and of the t(8; 14) have greatly improved our understanding of the pathogenesis of follicular and Burkitt's lymphoma. However, very little is known about the genes involved in DLCL, the most frequent subtype of lymphoma."
We have previously shown that translocations involving the 3q27 region and Ig genes locations were frequently observed in NHL, mainly of large cell type.I5 Breakpoints on chromosome 3 are clustered into an MTC of 4 kb, together with those of several chromosome rearrangements of the same 3q27 region that do not affect Ig genes as partner." We have cloned a gene, L A Z 3 , encoding an evolutionary conserved zinc finger protein, that is disrupted and abnormally overexpressed in patients with 3q27 molecular rearrangements, and postulated that the deregulation of this transcription factor (of unknown function) could be an important event in the pathogenesis of large cell lymphoma." The same breakpoint ~l u s t e r '~. '~ and the same genez0 have been cloned by others and named BCL-6.
To assess the frequency and the significance of LA23 rearrangements, we studied a series of 2 17 patients and found that the 3q27 region was affected in 13% of follicular lymphomas and 27% of DLCL. M 3 rearrangements appeared to be nearly restricted to B-cell lymphoma because only 1 of 39 immunologically characterized positive samples was of T-cell phenotype. In the group of aggressive lymphoma of B-cell phenotype, the overall frequency of LAZ3 rearrangements reaches 37%, in accordance with the results reported by Ye et al."
As suspected from the cytogenetic analy~is,'~ LAZ3 rearrangement was found in a proportion of follicular lymphoma cases (13%). These results differs from those of Ye et a 1 :
' who did not observe any BCL-6 alteration in a series of 28 patients with follicular lymphoma. The fact that LAZ3 rearrangement could be observed in some patients with follicular lymphoma at the time of diagnosis, and that it did not appear to influence survival, suggests that LAZ3 is not associated with clinical progression or histologic transformation.
Correlation with cytogenetic data showed that 1 1 of the 32 patients displaying a chromosomal defect of the 3q27 region had no LAZ3 rearrangement. In these cases, the defect could either affect another gene or, more likely, affect the LAZ3 gene at a breakpoint located outside the MTC. Thus, the reported frequency of LAZ3 involvement could represent an underestimation of the real frequency. On the other hand, 18 of the 39 patients with LAZ3 rearrangement and available cytogenetic results did not exhibit visible chromosomal break of the 3q27 region. This result suggests that almost 50% of LAZ3 rearrangements may be invisible by cytogenetic methods.
We were unable, in this series, to show any correlation between clinical characteristics and LAW rearrangement. Recently, Offit et alZ8 described an association between BCL-6 rearrangement and a subset of DLCL with high proportion of extranodal disease who enjoy a favorable outcome. Our study did not support this association. As both studies were retrospective, inclusion criteria might have been different. Our study included only patients with available cytogenetic data, and this fact probably discarded some patients with only extranodal localization at the time of diagnosis.
In conclusion, this study confirms the importance of alterations of LAZ3 in NHL, involving a third of the patients with aggressive B-cell lymphoma. Further studies are now required to understand the mechanism of action of this new oncogene, and to define whether or not its alterations have " . . any prognostic significance in NHL. This genomic marker, allowing the identification and follow-up of a homogeneous group of patients, will probably represent an important new approach to the diagnosis and management of patients with B-cell lymphoma. We are currently developing a polymerase chain reaction assay to assess minimal residual disease in patients with a t (3; 14) translocation.
